Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $2 | $2 |
| - Cash | $151 | $0 | $0 | $0 |
| + Debt | $31 | $0 | $0 | $0 |
| Enterprise Value | -$117 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 16.1% | 10.4% | -14% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 74.8% | 89.8% | 89.5% | 85% |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | -19.1% | 20.2% | 11.9% | 26% |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -23.5% | 13.6% | -7.9% | 8.8% |
| EPS Diluted | -0.8 | 0.4 | -0.21 | 0.27 |
| % Growth | -300% | 290.5% | -177.8% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |